Furthermore, all TC-1 tumor-bearing mice treated with cisplatin, E7 long peptide, and AnxA5 survived at least 70 days after tumor challenge, while 60% of mice in the cisplatin and E7 long peptide group died by day 50 after tumor challenge, and all mice in remaining treatment groups died by day 40 after tumor challenge (Fig. 1c). This evidence concerns the gene ANXA5 and neoplasm.